Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 8/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.39 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.36 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.35 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.33 |
| ▸ | GCK | P35557 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2472003 | 1.00 | OPRK1 (0.39) | OPRK1OPRM1OPRD1CXCR4RIPK1 | |
| SCHEMBL2473409 | 0.88 | OPRK1 (0.38) | OPRK1OPRM1OPRD1CXCR4KCNH2 | |
| SCHEMBL2477025 | 0.81 | P2RX7 (0.38) | OPRM1RIPK1ALDH1A1P2RX7OPRL1 | |
| SCHEMBL2474585 | 0.79 | CXCR4 (0.38) | CXCR4 | |
| SCHEMBL8305944 | 0.78 | OPRK1 (0.34) | OPRK1OPRM1OPRD1KCNH2KMT2A | |
| SCHEMBL2475559 | 0.77 | HDAC6 (0.43) | CXCR4 | |
| SCHEMBL8301794 | 0.77 | HDAC6 (0.43) | CXCR4 | |
| SCHEMBL2474699 | 0.77 | ALOX15 (0.38) | CXCR4ALDH1A1SMN1; SMN2 | |
| SCHEMBL2470444 | 0.77 | ALOX15 (0.38) | CXCR4ALDH1A1SMN1; SMN2 | |
| SCHEMBL2474177 | 0.73 | CXCR4 (0.35) | CXCR4P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090281308-A1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY | ANORMED, INC. (CA) | 2009-11-12 | — | — | US | disclosed |
| US-20090281308-A1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY | ANORMED, INC. (CA) | 2009-11-12 | — | — | US | disclosed |
| US-7550484-B2 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | GENZYME CORPORATION (US) | 2009-06-23 | — | — | US | disclosed |
| US-7550484-B2 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | GENZYME CORPORATION (US) | 2009-06-23 | — | — | US | disclosed |
| US-7501518-B2 | Methods of making 2,6-diaryl piperidine derivatives | GENZYME CORPORATION (US) | 2009-03-10 | — | — | US | disclosed |
| US-7501518-B2 | Methods of making 2,6-diaryl piperidine derivatives | GENZYME CORPORATION (US) | 2009-03-10 | — | — | US | disclosed |
| WO-2004093817-A2 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY | ANORMED INC. (CA) | 2004-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281308-A1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY | CXCR4, CXCR1, CCR5 | OPRK1 106/4885OPRM1 216/4885OPRD1 254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.